Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | CA12 | O43570 | 3/20 | 0.60 |
| ▸ | CA9 | Q16790 | 3/20 | 0.60 |
| ▸ | AR | P10275 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.51 |
| ▸ | AGER | Q15109 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7931393 | 0.83 | MAP2K1 (0.71) | ALDH1A1MAP2K1KDM4ECA12CA9 | |
| SCHEMBL4063682 | 0.83 | ALDH1A1 (0.53) | RAB9AALDH1A1MAP2K1KDM4ECA12 | |
| SCHEMBL4696347 | 0.82 | RAB9A (1.00) | RAB9AALDH1A1KDM4ECA12CA9 | |
| SCHEMBL3469941 | 0.82 | MAP2K1 (0.62) | RAB9AALDH1A1MAP2K1KDM4ECA12 | |
| SCHEMBL11446677 | 0.81 | AR (0.69) | ALDH1A1MAP2K1KDM4ECA12CA9 | |
| SCHEMBL6316379 | 0.81 | MAP2K1 (0.67) | ALDH1A1MAP2K1KDM4ECA12CA9 | |
| SCHEMBL17460094 | 0.80 | ALDH1A1 (0.55) | RAB9AALDH1A1MAP2K1KDM4ECA12 | |
| SCHEMBL3043823 | 0.79 | MAP2K1 (1.00) | ALDH1A1MAP2K1KDM4ECA12CA9 | |
| SCHEMBL13298959 | 0.78 | MAP2K1 (0.66) | RAB9AALDH1A1MAP2K1KDM4ECA12 | |
| SCHEMBL10770839 | 0.78 | RAB9A (0.67) | RAB9AALDH1A1KDM4ECA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104428036-A | Polypeptides and their use | NOVABIOTICS LTD | 2015-03-18 | — | — | CN | disclosed |
| EP-2825261-A1 | POLYPEPTIDES AND THEIR USE | Novabiotics Limited (GB) | 2015-01-21 | — | — | EP | disclosed |
| US-20140155321-A1 | Polypeptides and Their Use | NOVABIOTICS LIMITED (GB) | 2014-06-05 | — | — | US | disclosed |
| WO-2013136040-A1 | POLYPEPTIDES AND THEIR USE | NOVABIOTICS LIMITED (GB) | 2013-09-19 | — | — | WO | disclosed |
| US-20100267653-A1 | USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY | NOVABIOTICS LIMITED (GB) | 2010-10-21 | — | — | US | disclosed |
| EP-1799771-A2 | LIGHT ACTIVATED SHAPE MEMORY CO-POLYMERS | CORNERSTONE RESEARCH GROUP, INC. (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007001407-A2 | LIGHT ACTIVATED SHAPE MEMORY CO-POLYMERS | CORNERSTONE RESEARCH GROUP, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267653-A1 | USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY | DPM1, XPO5, NISCH | RAB9A 4757/4885ALDH1A1 1883/4885MAP2K1 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.